BOSTON, Massachusetts and BERGISCH GLADBACH, Germany, May 4, 2010 Stemgent, Inc., and Miltenyi Biotec today announced astrategic collaboration for co-development and commercialization of stem cellresearch products.
Within the strategic partnership, Miltenyi Biotec will be responsible forworldwide marketing and sales of Stemgent's existing stem cell productportfolio outside the USA, whereas Stemgent will continue to serve its UScustomers. Both companies will jointly develop innovative products to serveunmet needs of the international stem cell research community. New productsdeveloped in the strategic collaboration will be globally commercialized byMiltenyi Biotec on an exclusive basis.
Miltenyi Biotec will make an equity investment into Stemgent, and StefanMiltenyi, CEO of Miltenyi Biotec, will join Stemgent's Board of Directors."We are very pleased to form this relationship with Stemgent," said StefanMiltenyi. "Stemgent's accomplished track record in identifying superior toolsfor stem cell research perfectly complements Miltenyi Biotec's scientificexpertise and commitment to serving the biomedical research community withinnovative high-quality products throughout the world."
Commenting on the collaboration, Ian Ratcliffe, President and CEO ofStemgent, said, "Partnering with Miltenyi Biotec is a tremendous step forStemgent, as we instantly increase our global reach with a top-tier partnerallowing us to better serve our customers' needs. The co-development aspectdramatically increases our ability to combine Miltenyi Biotec's corporatetechnologies with Stemgent's stem cell expertise. We are especially pleasedto have Stefan join Stemgent's board and welcome Miltenyi Biotec as astrategic partner; Stefan's experience in building a world class organizationin the research tools space brings an invaluable perspective as we continueto build Stemgent."
About Miltenyi Biotec
Miltenyi Biotec's company mission is to improve scientific understandingand medical progress by providing products and services for cellulartherapies. With approx. 1100 employees in 18 countries, Miltenyi Biotecdevelops, manufactures and commercializes innovations for both, research andclinical applications. The portfolio provides integrated solutions for allareas covering sample preparation, cell separation, cell culture, flowcytometry, and molecular analysis. Visit http://www.miltenyibiotec.com todiscover more.
Stemgent advances stem cell science by providing proprietary reagents andtools developed by some of the world's leading stem cell scientists.Stemgent's product offering has been specifically optimized for and screenedagainst stem cells, and includes small molecules for pluripotency,self-renewal, and differentiation, viral-delivered transcription factors,matrices, cell lines, cytokines, antibodies, transfection reagents, and more.This unique product mix is designed to serve researchers who study stem cellbiology and regenerative medicine, and those who use cells derived from stemcells as tools to advance their understanding of major diseases. With dualheadquarters in Boston, Massachusetts, and San Diego, California, Stemgent iswell positioned to serve these major research markets. For more informationon Stemgent, please visit: http://www.stemgent.com.Contacts: Miltenyi Biotec Prof. Dr. Uwe Heinlein, Corporate Communications, Miltenyi Biotec GmbH +49-2204-8306-6590 email@example.com Stemgent Edward D. Agne, The Communications Strategy Group +1-781-631-3117 firstname.lastname@example.org
SOURCE Miltenyi Biotec GmbH